Get the Stockscreener App
108.18
0.92%
-1.00
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $108.18, with a volume of 10.48M.
It is down -0.92% in the last 24 hours and up +2.99% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$109.18
Open:
$109.09
24h Volume:
10.48M
Relative Volume:
0.78
Market Cap:
$268.51B
Revenue:
$63.90B
Net Income/Loss:
$19.05B
P/E Ratio:
14.31
EPS:
7.5596
Net Cash Flow:
$13.05B
1W Performance:
-0.60%
1M Performance:
+2.99%
6M Performance:
+28.82%
1Y Performance:
+11.95%
1-Day Range:
$107.21
$109.09
1-Week Range:
$106.93
$111.97
52-Week Range:
$73.31
$112.90
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
108.18 | 270.99B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co., Inc. (MRK) and CEPI Launch Effort to Make Ebola Vaccine Cheaper and Easier to Distribute - Insider Monkey
Merck & Co., Inc. $MRK Shares Sold by TFR Capital LLC. - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by Sector Gamma AS - MarketBeat
Sagespring Wealth Partners LLC Purchases 13,778 Shares of Merck & Co., Inc. $MRK - MarketBeat
iA Global Asset Management Inc. Reduces Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Cullen Frost Bankers Inc. - MarketBeat
Commerzbank Aktiengesellschaft FI Has $29.15 Million Position in Merck & Co., Inc. $MRK - MarketBeat
1 ETF Could Turn $500 Monthly Into a $800,000 Portfolio That Pays $24,000 in Annual Dividend Income - The Motley Fool
Merck & Co., Inc. $MRK Shares Sold by Symphony Financial Ltd. Co. - MarketBeat
Mn Services Vermogensbeheer B.V. Has $80.17 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Purchases 142,125 Shares of Merck & Co., Inc. $MRK - MarketBeat
UniSuper Management Pty Ltd Buys 160,345 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock - Chartmill
ARGA Investment Management LP Cuts Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Teacher Retirement System of Texas Sells 199,740 Shares of Merck & Co., Inc. $MRK - MarketBeat
UNIVEST FINANCIAL Corp Sells 18,610 Shares of Merck & Co., Inc. $MRK - MarketBeat
Strs Ohio Boosts Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Merck & Co., Inc. (NYSE:MRK) Shares Down 1.7%Here's What Happened - MarketBeat
How To Win Deals In A Competitive Market, With Merck & Co. BD Exec Elizabeth Naldi-Jacob - Citeline News & Insights
User - The Chronicle-Journal
Merck unit partners with global health coalition to develop affordable Ebola vaccine - Reuters
Simplicity Wealth LLC Sells 43,336 Shares of Merck & Co., Inc. $MRK - MarketBeat
Boston Common Asset Management LLC Has $20.79 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Bailard Inc. Sells 30,041 Shares of Merck & Co., Inc. $MRK - MarketBeat
Allergic Rhinitis Treatment Market Is Booming Worldwide | Merck - openPR.com
Merck added to BofA's best ideas list—see all the names - Seeking Alpha
Merck & Co., Inc. (NYSE:MRK) Stock Price Up 1.5% on Analyst Upgrade - MarketBeat
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
Merck & Co., Inc. $MRK Stock Position Boosted by Joel Isaacson & Co. LLC - MarketBeat
Broader Analyst Sentiment Bullish on Merck & Co. (MRK) Amid Tempered Short-Term Expectation and Long-Term Optimism - Finviz
Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s - Insider Monkey
Merck stock added to BofA US 1 List, Apple remains on select portfolio - Investing.com
Dynasty Wealth Management LLC Takes $1.02 Million Position in Merck & Co., Inc. $MRK - MarketBeat
MRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. In - The National Law Review
Merck/Moderna Intismeran Data Show Continued Efficacy In Melanoma - Citeline News & Insights
Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma - Benzinga
Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up - Reuters
Merck (MRK) Builds Post-Keytruda Growth Plan, BMO Upgrades to Outperform - Finviz
Merck & Co (MRK) Analyst Rating: TD Cowen Raises Price Target to $120 | MRK Stock News - GuruFocus
Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
Merck & Co., Inc. Stock (MRK) Opinions on Pipeline Revenue Projections - Quiver Quantitative
Turtle Creek Wealth Advisors LLC Cuts Position in Merck & Co., Inc. $MRK - MarketBeat
Moderna-Merck Skin Cancer Treatment Shows Long-Term Benefits - Bloomberg
Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion - Finviz
Merck & Co., Inc. (NYSE:MRK) S&P 500 Fund Healthcare Scale - Kalkine Media
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF MERCK & CO. INC. lobbying was just disclosed - Quiver Quantitative
Wealth Enhancement Advisory Services LLC Acquires 98,009 Shares of Merck & Co., Inc. $MRK - MarketBeat
NorthCrest Asset Manangement LLC Buys 81,276 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stake Lowered by Massachusetts Financial Services Co. MA - MarketBeat
Allstate Corp Increases Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):